 NEWTOWN, Pa., Nov. 23, 2020 GLOBE NEWSWIRE -- Onconova Therapeutics, Inc. NASDAQ: ONTX, a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the filing of an Investigational New Drug application IND with the U.S. Food and Drug Administration FDA for ON 123300, the Companys proprietary, differentiated, first-in-class multi-kinase inhibitor. The IND seeks permission to begin a Phase 1 trial with ON 123300 in relapsedrefractory advanced cancer including patients with HR HER 2- metastatic breast cancer with resistance to approved second-generation CDK46 inhibitors. 